Profile data is unavailable for this security.
About the company
Worldwide Healthcare Trust PLC is a specialist investment trust. The Company invests in the global healthcare sector with the objective of achieving a high level of capital growth. It invests worldwide in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector. It invests up to 10% of the portfolio, at the time of acquisition, in unquoted securities. It invests approximately 50% of the portfolio in larger companies, and at over 20% of the portfolio in smaller companies. It may invest over 5% of the portfolio, at the time of acquisition, in debt instruments, convertibles and royalty bonds issued by pharmaceutical and biotechnology companies. It may invest over 30% of the portfolio in companies under sectors, such as healthcare equipment and supplies, and healthcare providers and services. Its alternative investment fund manager is Frostrow Capital LLP. OrbiMed Capital LLC is its portfolio manager.
- Revenue in GBP (TTM)-66.33m
- Net income in GBP-95.44m
- Incorporated1995
- Employees0.00
- LocationWorldwide HealthcareFrostrow Capital LLP25 Southampton BuildingsLONDON WC2A 1ALUnited KingdomGBR
- Phone+44 20 3008 4910
- Websitehttps://www.worldwidewh.com/
Profile
| Management group(s) | Frostrow Capital LLP |
|---|---|
| AIC sector | Biotechnology & Healthcare |
| ISIN | GB00BN455J50 |
| Launch date | 28 Apr 1995 |
| Share type | Ordinary Share |
| Structure | Investment Trust |
| Base currency | GBP |
Objective
In order to achieve a high level of capital growth, the Company invests in the global healthcare sector and in a diversified portfolio of shares in pharmaceutical and biotechnology companies and related securities in the healthcare sector. It uses gearing, and derivative transactions to mitigate risk and also to enhance returns.
Managed by
| Sven H. Borho, Trevor M. Polischuk |
|---|
Management & contract fees
The Investment Manager receives a fee equal to 0.65% p.a. of the NAV of Company. The performance fee amounts to 15% of any outperformance of the NAV over the benchmark index. The Company may be terminated by either party giving notice of not less than 12 months.
Peer analysis
| Company | Revenue (TTM) | Net income (TTM) |
|---|---|---|
| Bonesupport Holding AB | 48.12m | 19.56m |
| Fagron NV | 652.99m | 60.38m |
| Genus plc | 673.10m | 33.40m |
| Biotest AG | 585.90m | 108.69m |
| Bavarian Nordic A/S | 810.42m | 169.28m |
| Dermapharm Holding SE | 971.67m | 53.38m |
| Evotec SE | 668.77m | -71.82m |
| Galapagos NV | 245.62m | -3.41m |
| Almirall SA | 765.55m | -32.93m |
| Vitrolife AB | 256.78m | -281.51m |
| Worldwide Healthcare Trust PLC | -66.33m | -95.44m |
| Indivior PLC | 896.97m | 3.99m |
| BB BIOTECH AG | 237.21m | 269.63m |
| Camurus AB | 125.99m | 31.66m |
| MorphoSys AG | 174.16m | -390.55m |
| Virbac SA | 1.07bn | 103.81m |
Institutional shareholders
| Holder | Shares | % Held |
|---|---|---|
| Rathbones Investment Management Ltd.as of 21 Sep 2023 | 48.86m | 8.93% |
| Investec Wealth & Investment Ltd.as of 21 Sep 2023 | 44.60m | 8.15% |
| Hargreaves Lansdown Asset Management Ltd.as of 30 Apr 2023 | 36.29m | 6.63% |
| Forsyth Barr Ltd.as of 30 Apr 2023 | 31.23m | 5.71% |
| Quilter Cheviot Ltd.as of 30 Apr 2023 | 22.24m | 4.07% |
| Brewin Dolphin Ltd.as of 30 Apr 2023 | 21.79m | 3.98% |
| Craigs Investment Partners Ltd. (Investment Management)as of 30 Apr 2023 | 21.35m | 3.90% |
| Evelyn Partners Investment Management LLPas of 30 Apr 2023 | 18.38m | 3.36% |
| Close Asset Management Ltd.as of 01 Apr 2024 | 12.25m | 2.24% |
| J. M. Finn & Co. Ltd.as of 01 Apr 2024 | 7.25m | 1.33% |
